Vision Risks With Weight-Loss Drugs Semaglutide and Topiramate Explored
A detailed comparison reveals potential vision issues linked to popular weight-loss medications.
Recent research highlights increased risks of vision complications, including optic neuropathy and glaucoma, associated with weight-loss drugs like semaglutide and topiramate, emphasizing the importance of patient-specific treatment choices.
Study Details:
Investigations into the ocular side effects of weight-loss medications have uncovered significant vision risks, particularly related to GLP-1 receptor agonists like semaglutide and medications containing topiramate. These findings are crucial given the surge in prescriptions for these medications amid rising obesity rates.
Methodology:
Researchers from Massachusetts Eye and Ear Hospital conducted a retrospective analysis involving nearly 2,000 patients, assessing the incidence of nonarteritic anterior ischemic optic neuropathy (NAION) linked to semaglutide use. Additionally, several studies reviewed data from FDA adverse event reports (FAERS) to evaluate the incidence of vision impairment and glaucoma associated with topiramate and other drugs.
Key Findings:
Patients taking semaglutide showed a four to seven times higher risk of developing NAION compared to non-users.
Topiramate use was notably associated with a 30% higher likelihood of vision impairment reports, including optic neuropathy, acute myopia, and angle-closure glaucoma.
Despite these risks, GLP-1 receptor agonists may offer protection against glaucoma in non-diabetic, obese individuals.
Phentermine, although linked to blurred vision and serious ocular events, showed a reduced future risk of diabetic retinopathy in overweight patients.
Implications for Practice:
Healthcare providers should carefully evaluate individual patient profiles, including existing eye conditions and diabetes status, when prescribing weight-loss medications. While GLP-1 receptor agonists are generally effective, their potential ocular risks necessitate cautious use and vigilant monitoring.
For patients already experiencing vision loss, informed discussions about the balance between weight management benefits and vision health risks are essential.